# Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

> **NCT02501473** · PHASE1,PHASE2 · TERMINATED · sponsor: **Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 52 (actual)

## Conditions studied

- Follicular Low Grade Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** G100
- **DRUG:** Pembrolizumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02501473
- **Lead sponsor:** Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-03
- **Primary completion:** 2019-08-01
- **Final completion:** 2019-08-01
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2020-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501473, "Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02501473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*